| ₹ crore | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | 228 | 239 | −4.5% |
| EBITDA | 128 | 136 | −6.1% |
| EBITDA margin | 56.0% | 56.9% | −1.0 pts |
| Profit before tax | 136 | 143 | −5.4% |
| Net profit | 105 | 119 | −11.5% |
| EPS | ₹14.93 | ₹16.88 | −11.6% |
Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.
| Tap a line for its trend | Currentlast 12M | FY26Mar 2026 | FY25Mar 2025 | FY24Mar 2024 | FY23Mar 2023 | FY22 and earlierAlpha Plus |
|---|
| 7,081 | — | — | — | — | FY22 and earlierEvery year the company has filed comes with Alpha Plus. | |
| 473 | 373 | 261 | 352 | 405 | ||
| 6,608 | — | — | — | — | ||
| 940 | 932 | 732 | 678 | 546 | ||
| — | +27.3% | +7.9% | +24.2% | — | ||
| 474 | 490 | 438 | 372 | 349 | ||
| 50.4% | 52.6% | 59.8% | 54.9% | 63.9% | ||
| 425 | 441 | 388 | 372 | 316 | ||
| 403 | 413 | 375 | — | 291 | ||
| 42.9% | 44.3% | 51.3% | — | 53.2% | ||
| ₹57.18 | ₹58.59 | ₹53.26 | — | ₹41.25 | ||
| — | +10.0% | — | — | — | ||
| — | 388 | 349 | 376 | 297 | ||
| — | −322 | −784 | — | −8.6 | ||
| 65.5 | 65.5 | −436 | 376 | 288 | ||
From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.
In ₹ Crore except Per Share 12 Months Ending | FY23 31/03/2023 | FY24 31/03/2024 | FY25 31/03/2025 | FY26 31/03/2026 | Current/LTM TTM · last close | |
|---|---|---|---|---|---|---|
| Market Capitalization | — | — | — | — | 7,080.9 | |
| - Cash, Equiv & ST Investments | 405.5 | 352.3 | 261.4 | 373.3 | 473.3 | |
| Enterprise Value | — | — | — | — | 6,607.6 | |
| Revenue | 546.0 | 678.2 | 732.0 | 932.1 | 939.8 | |
| Growth %, YoY | — | +24.2 | +7.9 | +27.3 | — | |
| EBITDA | 348.7 | 372.1 | 437.7 | 490.4 | 474.1 | |
| Margin % | 63.87 | 54.87 | 59.80 | 52.61 | 50.45 | |
| EBIT | 315.9 | 372.1 | 387.8 | 441.3 | 425.3 | |
| Net Income | 290.6 | — | 375.2 | 412.7 | 402.9 | |
| Margin % | 53.23 | — | 51.26 | 44.28 | 42.87 | |
| EPS, Adj (current shares) | 41.25 | — | 53.26 | 58.59 | 57.18 | |
| Growth %, YoY | — | — | — | +10.0 | — | |
| Cash from Operations | 296.6 | 375.5 | 348.9 | 387.8 | — | |
| Capital Expenditures | -8.6 | — | -784.4 | -322.3 | — | |
| Free Cash Flow | 288.0 | 375.5 | -435.5 | 65.5 | 65.5 | |
Prices at the 29 October 2026 close · figures from the company's filings with NSE
NESCO (NSE: NESCO) had a market capitalisation of ₹7,053 crore at the 29 October 2026 close (₹1,001.20 a share), a PE ratio of 17.5 on the last four quarters' profit and a price-to-book ratio of 2.24. In FY26 its consolidated net profit was ₹413 crore on revenue of ₹932 crore; in Q2 FY27 (July–September 2026) it was ₹105 crore, down 11.5% year on year. It had no borrowings on 30 September 2026. Promoters held 68.54% of the shares on 30 September 2026.
NESCO's PE ratio is 17.5 at the 29 October 2026 close (₹1,001.20 a share): a market capitalisation of ₹7,053 crore divided by consolidated net profit of ₹403 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹413 crore) it is 17.1.
NESCO's net worth — shareholders' equity in its consolidated balance sheet — was ₹3,152 crore on 30 September 2026, up 12.6% from ₹2,799 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹7,053 crore at the 29 October 2026 close.
NESCO's book value per share was ₹447.46 on 30 September 2026: shareholders' equity of ₹3,152 crore divided by the 7.05 crore shares in issue, up 12.6% from ₹397.26 a year earlier. The share price at the 29 October 2026 close was ₹1,001.20.
NESCO's price-to-book (PB) ratio is 2.24 at the 29 October 2026 close: a market capitalisation of ₹7,053 crore divided by shareholders' equity (book value) of ₹3,152 crore on 30 September 2026. That is a book value of ₹447.46 per share against a share price of ₹1,001.20.
In FY26, NESCO's return on equity (ROE) was 14.7% and its return on capital employed (ROCE) was 13.9%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 15.2% and ROCE 14.5%.
NESCO's dividend yield is 0.70% at the 29 October 2026 close: dividends of ₹7 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹1,001.20. They were ₹7 on 20 July 2026.
NESCO's market capitalisation was ₹7,053 crore at the 29 October 2026 close: 7.05 crore shares at ₹1,001.20 each.
Yes. NESCO had no borrowings on 30 September 2026 (consolidated balance sheet), and it held ₹485 crore of cash, bank balances and current investments.
NESCO's debt-to-equity ratio was 0.00 on 30 September 2026: no borrowings against total equity of ₹3,152 crore. A year earlier, on 30 September 2025, it was 0.00.
NESCO's basic earnings per share (EPS) were ₹58.58 in FY26, against ₹53.25 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹57.18.
In 2026, NESCO has declared one dividend: ₹7 with record date 20 July 2026.
Promoters held 68.54% of NESCO on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
On 30 September 2026, NESCO's shares were held by promoters 68.54%, foreign portfolio investors (FII/FPI) 4.19%, domestic institutions (DII) 4.27% (including mutual funds at 3.19%) and retail and other non-institutional investors 23.00%. Over the year, FII holding was down 0.71 percentage points from 4.90% and DII holding was up 0.30 percentage points from 3.97%.
At the 29 October 2026 closing prices, on FY26 net profit, NESCO's PE ratio is 17.1, the lowest of the three: MSTC 18.4 and Medplus Health Services 32.7, a peer average of 25.6. Each is the company's market capitalisation at that price divided by its FY26 net profit.
In FY26, NESCO earned net profit of ₹413 crore on revenue of ₹932 crore, against ₹218 crore on ₹370 crore for MSTC. NESCO's operating margin was 47.4% (MSTC 57.8%) and its return on equity 14.7% (MSTC 26.6%). At the 29 October 2026 close, NESCO's market capitalisation was ₹7,053 crore against ₹4,027 crore for MSTC, and its PE ratio on FY26 profit 17.1 against 18.4.
In FY26, NESCO generated ₹388 crore of cash from operations and spent ₹322 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹65.5 crore. In FY25 it was −₹436 crore.
NESCO's latest results are for Q2 FY27 (July–September 2026), filed on 23 October 2026: consolidated net profit ₹105 crore, down 11.5% from ₹119 crore in Q2 FY26; revenue from operations ₹228 crore, down 4.5% year on year.
NESCO has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.
In FY26 (April 2025–March 2026), NESCO's consolidated net profit was ₹413 crore, up 10.0% from ₹375 crore in FY25, on revenue from operations of ₹932 crore (up 27.3%). Over three years, from FY23, net profit was up 42.0%.
On FY26 consolidated figures, against MSTC and Medplus Health Services: NESCO's operating margin of 47.4% is the second highest of the three (MSTC 57.8%, Medplus Health Services 4.7%; peer average 31.3%); its return on equity of 14.7% is the second highest of the three (MSTC 26.6%, Medplus Health Services 11.8%; peer average 19.2%); its revenue growth over three years of 19.5% a year is the highest of the three (MSTC −20.0% a year, Medplus Health Services 14.8% a year; peer average −2.6% a year).
From NESCO's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.